7S6O image
Entry Detail
PDB ID:
7S6O
Title:
The crystal structure of Lys48-linked di-ubiquitin
Biological Source:
Source Organism:
Host Organism:
PDB Version:
Deposition Date:
2021-09-14
Release Date:
2021-09-22
Method Details:
Experimental Method:
Resolution:
1.25 Å
R-Value Free:
0.17
R-Value Work:
0.12
R-Value Observed:
0.13
Space Group:
P 1 21 1
Macromolecular Entities
Polymer Type:polypeptide(L)
Description:Ubiquitin
Mutations:K48R
Chain IDs:A
Chain Length:76
Number of Molecules:1
Biological Source:Homo sapiens
Polymer Type:polypeptide(L)
Description:Ubiquitin
Mutations:Aspartic acid residue added to C terminus (D77)
Chain IDs:B
Chain Length:77
Number of Molecules:1
Biological Source:Homo sapiens
Ligand Molecules
Primary Citation
Dual domain recognition determines SARS-CoV-2 PLpro selectivity for human ISG15 and K48-linked di-ubiquitin.
Nat Commun 14 2366 2366 (2023)
PMID: 37185902 DOI: 10.1038/s41467-023-38031-5

Abstact

The Papain-like protease (PLpro) is a domain of a multi-functional, non-structural protein 3 of coronaviruses. PLpro cleaves viral polyproteins and posttranslational conjugates with poly-ubiquitin and protective ISG15, composed of two ubiquitin-like (UBL) domains. Across coronaviruses, PLpro showed divergent selectivity for recognition and cleavage of posttranslational conjugates despite sequence conservation. We show that SARS-CoV-2 PLpro binds human ISG15 and K48-linked di-ubiquitin (K48-Ub2) with nanomolar affinity and detect alternate weaker-binding modes. Crystal structures of untethered PLpro complexes with ISG15 and K48-Ub2 combined with solution NMR and cross-linking mass spectrometry revealed how the two domains of ISG15 or K48-Ub2 are differently utilized in interactions with PLpro. Analysis of protein interface energetics predicted differential binding stabilities of the two UBL/Ub domains that were validated experimentally. We emphasize how substrate recognition can be tuned to cleave specifically ISG15 or K48-Ub2 modifications while retaining capacity to cleave mono-Ub conjugates. These results highlight alternative druggable surfaces that would inhibit PLpro function.

Legend

Protein

Chemical

Disease

Primary Citation of related structures